Michele Maio


Ontology type: schema:Person     


Person Info

NAME

Michele

SURNAME

Maio

Publications in SciGraph latest 50 shown

  • 2019-01 Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2019-01 The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2019-01 Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2018-08 Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2018-06 Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2018-03-20 Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma in BRITISH JOURNAL OF CANCER
  • 2018-01 Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2017-12 Predictors of responses to immune checkpoint blockade in advanced melanoma in NATURE COMMUNICATIONS
  • 2017-12 Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab in ENDOCRINE
  • 2016-11 “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-07 Melanoma and immunotherapy bridge 2015 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016 ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies in TUMOR IMMUNOLOGY
  • 2016-01 “Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2015-12 coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-08 Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2015-03 Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 in CELL RESEARCH
  • 2015-02 Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 in CELL RESEARCH
  • 2015-01 CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2015-01 “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-12 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-12 Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2014-12 Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-05 Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology in JOURNAL OF INVESTIGATIVE DERMATOLOGY
  • 2014-05 Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases in JOURNAL OF NEURO-ONCOLOGY
  • 2014-04 Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy in BRITISH JOURNAL OF CANCER
  • 2014 Epigenetic Markers of Prognosis in Melanoma in MOLECULAR DIAGNOSTICS FOR MELANOMA
  • 2013-12 Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-12 Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-12 Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2013-11 Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-11 Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-06 Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-05 Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-03 Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-12 The cost of unresectable stage III or stage IV melanoma in Italy in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2012-12 Cancer classification using the Immunoscore: a worldwide task force in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 The role of BRAF V600 mutation in melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-12 Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2012-09 Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications in BRITISH JOURNAL OF CANCER
  • 2012-09 Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-01 Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2011-12 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th2010" in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2011-12 Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2011-12 Defining the critical hurdles in cancer immunotherapy in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2011-07 Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success? in BRITISH JOURNAL OF CANCER
  • 2011-06 Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2011-04 Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2010-12 Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies in JOURNAL OF TRANSLATIONAL MEDICINE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.411477.0", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418321.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.15667.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4691.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9024.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.1011.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417893.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10392.39", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415190.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417988.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.260917.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419546.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476288.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.11451.30", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.121334.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417520.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419617.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.6363.0", 
            "type": "Organization"
          }
        ], 
        "familyName": "Maio", 
        "givenName": "Michele", 
        "id": "sg:person.01061427172.10", 
        "identifier": {
          "name": "orcid_id", 
          "type": "PropertyValue", 
          "value": [
            "0000-0002-0323-6321"
          ]
        }, 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061427172.10", 
          "https://orcid.org/0000-0002-0323-6321"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:01", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_718.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01061427172.10'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01061427172.10'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01061427172.10'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01061427172.10'


     

    This table displays all metadata directly associated to this object as RDF triples.

    55 TRIPLES      11 PREDICATES      30 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.01061427172.10 schema:affiliation N09e6a38d9e46432b81927f8e9b7843c9
    2 https://www.grid.ac/institutes/grid.1011.1
    3 https://www.grid.ac/institutes/grid.10392.39
    4 https://www.grid.ac/institutes/grid.11451.30
    5 https://www.grid.ac/institutes/grid.121334.6
    6 https://www.grid.ac/institutes/grid.15667.33
    7 https://www.grid.ac/institutes/grid.260917.b
    8 https://www.grid.ac/institutes/grid.415190.8
    9 https://www.grid.ac/institutes/grid.417520.5
    10 https://www.grid.ac/institutes/grid.417893.0
    11 https://www.grid.ac/institutes/grid.417988.b
    12 https://www.grid.ac/institutes/grid.418321.d
    13 https://www.grid.ac/institutes/grid.419546.b
    14 https://www.grid.ac/institutes/grid.419617.c
    15 https://www.grid.ac/institutes/grid.4691.a
    16 https://www.grid.ac/institutes/grid.476288.7
    17 https://www.grid.ac/institutes/grid.6363.0
    18 https://www.grid.ac/institutes/grid.9024.f
    19 schema:familyName Maio
    20 schema:givenName Michele
    21 schema:identifier Nccd0ec8509ba493a8bced0f22a5f85e7
    22 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061427172.10
    23 https://orcid.org/0000-0002-0323-6321
    24 schema:sdDatePublished 2019-03-07T15:01
    25 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    26 schema:sdPublisher N9b3b8f4429bf4e84ae2e5988eef8421e
    27 sgo:license sg:explorer/license/
    28 sgo:sdDataset persons
    29 rdf:type schema:Person
    30 N09e6a38d9e46432b81927f8e9b7843c9 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
    31 sgo:isCurrent true
    32 rdf:type schema:OrganizationRole
    33 N9b3b8f4429bf4e84ae2e5988eef8421e schema:name Springer Nature - SN SciGraph project
    34 rdf:type schema:Organization
    35 Nccd0ec8509ba493a8bced0f22a5f85e7 schema:name orcid_id
    36 schema:value 0000-0002-0323-6321
    37 rdf:type schema:PropertyValue
    38 https://www.grid.ac/institutes/grid.1011.1 schema:Organization
    39 https://www.grid.ac/institutes/grid.10392.39 schema:Organization
    40 https://www.grid.ac/institutes/grid.11451.30 schema:Organization
    41 https://www.grid.ac/institutes/grid.121334.6 schema:Organization
    42 https://www.grid.ac/institutes/grid.15667.33 schema:Organization
    43 https://www.grid.ac/institutes/grid.260917.b schema:Organization
    44 https://www.grid.ac/institutes/grid.411477.0 schema:Organization
    45 https://www.grid.ac/institutes/grid.415190.8 schema:Organization
    46 https://www.grid.ac/institutes/grid.417520.5 schema:Organization
    47 https://www.grid.ac/institutes/grid.417893.0 schema:Organization
    48 https://www.grid.ac/institutes/grid.417988.b schema:Organization
    49 https://www.grid.ac/institutes/grid.418321.d schema:Organization
    50 https://www.grid.ac/institutes/grid.419546.b schema:Organization
    51 https://www.grid.ac/institutes/grid.419617.c schema:Organization
    52 https://www.grid.ac/institutes/grid.4691.a schema:Organization
    53 https://www.grid.ac/institutes/grid.476288.7 schema:Organization
    54 https://www.grid.ac/institutes/grid.6363.0 schema:Organization
    55 https://www.grid.ac/institutes/grid.9024.f schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...